- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
- Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
- Medicare Issues Final Coverage Determination for kidneyintelX.dkd
- Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
- Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
- Renalytix Announces Financing with Expected Size of up to $4 Million
- KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
- Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
- Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
More ▼
Key statistics
On Friday, Renalytix PLC (RENX:LSE) closed at 8.25, 12.24% above the 52 week low of 7.35 set on Oct 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.25 |
---|---|
High | 8.25 |
Low | 8.00 |
Bid | 7.50 |
Offer | 9.50 |
Previous close | 8.25 |
Average volume | 190.19k |
---|---|
Shares outstanding | 165.93m |
Free float | 106.59m |
P/E (TTM) | -- |
Market cap | 13.70m GBP |
EPS (TTM) | -0.4314 GBP |
Data delayed at least 15 minutes, as of Oct 04 2024 15:32 BST.
More ▼